EP2007367A1 - Medicated feed premix comprising chlortetracycline hydrochloride - Google Patents

Medicated feed premix comprising chlortetracycline hydrochloride

Info

Publication number
EP2007367A1
EP2007367A1 EP07751014A EP07751014A EP2007367A1 EP 2007367 A1 EP2007367 A1 EP 2007367A1 EP 07751014 A EP07751014 A EP 07751014A EP 07751014 A EP07751014 A EP 07751014A EP 2007367 A1 EP2007367 A1 EP 2007367A1
Authority
EP
European Patent Office
Prior art keywords
medicated feed
feed premix
medicated
premix
chlortetracycline hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07751014A
Other languages
German (de)
French (fr)
Other versions
EP2007367B1 (en
Inventor
Robert Cornez
Steven Holmes
Dirk Van Malcot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpharma LLC
Original Assignee
Alpharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Inc filed Critical Alpharma Inc
Priority to SI200730506T priority Critical patent/SI2007367T1/en
Publication of EP2007367A1 publication Critical patent/EP2007367A1/en
Application granted granted Critical
Publication of EP2007367B1 publication Critical patent/EP2007367B1/en
Priority to CY20111100108T priority patent/CY1111176T1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Definitions

  • Antibiotics such as tetracyclines, are used as growth promoters and feed efficiency promoters in animals such as poultry and livestock, and for therapeutic and prophylactic disease control in animals such as poultry and livestock, fish, domesticated pets, and so forth.
  • antibiotics are typically formulated in a medicated animal feed premix or animal feed supplement containing the antibiotic and an edible carrier or diluent. These premixes or animal feed supplements may then be mixed with a sufficient quantity of an appropriate animal foodstuff (e.g., livestock, poultry, fish, pet and/or other animal feed) to provide a final animal feed formulation having the desired level of antibiotic in the feed.
  • an appropriate animal foodstuff e.g., livestock, poultry, fish, pet and/or other animal feed
  • Typical prior art chlortetracycline-containing animal feed premixes are prepared through normal fermentation and dehydration of the mycelium meal, which is added directly to the feed premix.
  • Streptomyces aureofaciens is a microbial source organism for chlortetracycline. Under a normal fermentation and dehydration processes, feed premixes comprising about 20 wt% or less of chlortetracycline have been produced.
  • U.S. Patent Number 6,844,006 describes animal feed premixes containing greater than 35 wt% chlortetracycline produced using a novel fermentation process in which the chlortetracycline is also added directly from a fermentation product.
  • tetracycline e.g, chlortetracycline
  • animal feed premixes Another problem with prior tetracycline (e.g, chlortetracycline) animal feed premixes is the stability of the tetracycline in these premixes. Because tetracyclines are water soluble, there is intrinsically an issue with stability in finished feeds containing moistures of 10% or higher. The higher water activity (relative vapor pressure) of feedstuff compared to tetracycline leads to an inevitable increase of the humidity of most formulations.
  • an a medicated feed premix composition comprising 15 wt% to 65 wt% of a pharmaceutically acceptable chlortetracycline hydrochloride, 20 wt% to 85 wt% of a carrier, and 0.1 wt% to 10 wt% of a binder, wherein all amounts are based on the total weight of the medicated feed premix.
  • an animal feed composition comprising an. effective amount of the medicated feed premix.
  • a chlortetracycline hydrochloride in the manufacture of a medicament for treating microbial infections in animals.
  • the medicament comprises 15 wt% to 65 wt% of a pharmaceutically acceptable chlortetracycline hydrochloride, 20 wt% to 85 wt% of a carrier, and 0.1 wt% to 10 wt% of abinder, wherein all amounts are based on the total weight of the medicament.
  • a method of making an a medicated feed premix comprises forming a mixture comprising 15 wt% to 65 wt% of a pharmaceutically acceptable chlortetracycline hydrochloride, 20 wt% to 85 wt% of a carrier, ' 0.1 wt% to 10 wt% of a binder, wherein all amounts are based on the total weight of the medicated feed premix; and granulating the mixture to form a granulate.
  • a medicated feed premix comprises 15 wt% to 65 wt% of a pharmaceutically acceptable tetracycline hydrochloride, 20 wt% to 85 wt% of a carrier, and 0.1 wt% to 10 wt% of a binder, wherein all amounts are based on the total weight of the animal feed supplement, and wherein the medicated feed premix is in the form of a granulate and has a pH of 3 to 4.
  • Figure 1 illustrates degradation routes of chlortetracycline. DETAILED DESCRIPTION
  • medicated feed premixes comprising pharmaceutically acceptable tetracycline (e.g., chlortetracycline hydrochloride), a binder, and a carrier.
  • tetracycline e.g., chlortetracycline hydrochloride
  • a “medicated feed premix” refers to a composition suitable for incorporation into the diet of an animal through incorporation into the animal's food and/or water.
  • the medicated feed premix is in the form of a granulate.
  • Medicated feed premixes are also referred to as feed "supplement" compositions and "feed additive" compositions.
  • tetracycline includes tetracycline, chlortetracycline, oxytetracycline, doxycycline, demeclocycline, lymecycline, meclocycline, methacycline, minocycline, rolitetracycline, and combinations comprising one or more of the foregoing tetracyclines. Included in the term tetracycline are salts, esters, ethers, isomers, mixtures of isomers, complexes or derivatives of the free compoundand combinations comprising one or more of the foregoing tetracyclines! In one embodiment, the tetracycline is chlortetracycline hydrochloride.
  • chlortetracycline hydrochloride is the reference standard for chlortetracycline feed grade materials, all chlortetracycline concentrations and percentages stated herein, unless indicated otherwise, are calculated as the hydrochloride equivalent, regardless of the form present (e.g., the free base, complexes or salts other than the hydrochloride, etc.)
  • pharmaceutically acceptable chlortetracycline hydrochloride comprises a minimum of 89.5 wt% anhydrous chlortetracycline hydrochloride and a maximum of 8 wt% anhydrous tetracycline, with a 94.5-102 wt% sum of anhydrous chlortetracycline hydrochloride plus anhydrous tetracycline hydrochloride.
  • the medicated feed premixes described herein can be distinguished from prior art tetracycline medicated feed premixes in that the medicated feed premixes described herein comprise pharmaceutically acceptable tetracycline.
  • chlortetracycline hydrochloride for example, is typically prepared by chemical purification of chlortetracycline hydrochloride produced by fermentation, typically of Streptomyces aureofaciens.
  • Prior art chlortetracycline medicated feed premixes contain chlortetracycline hydrochloride in the form of a crude fermentation product such as that produced by dehydration of the mycelium meal.
  • pharmaceutically acceptable chlortetracycline is produced by chemical purification.
  • the chlortetracycline hydrochloride is not produced from genetically modified organisms.
  • the pharmaceutically acceptable tetracycline (e.g., chlortetracycline hydrochloride) comprises 15 wt% to 65 wt% of the total weight of the medicated feed premix, specifically 20 wt% to 65 wt% of the total weight of the medicated feed premix, more specifically 25 wt% to 65 wt% of the medicated feed premix, and most specifically 25 wt% to 60 wt% of the medicated feed premix.
  • the medicated feed premix also comprises a binder.
  • binder is well known to those of skill in the art as an agent that holds the components of the formulation together. Suitable binders include, for example, sodium carboxymethylcellulose, hydroxyprppylmethylcellulose, gelatin, polyvinylpyrrolidone (PVP), polyvinylalcohol, polyvinylether, hydroxypropylcellulose, potassium alginate, sodium alginate, ethyl cellulose, methylcellulose, macrocrystalline cellulose, starch such as partially pregelatinized corn starch, and combinations comprising one or more of the foregoing binders.
  • the binder comprises sodium carboxymethylcellulose.
  • the binder comprises 0.1 wt%. to 10 wt% of the total weight of the medicated feed premix, specifically 0.2 wt% to 5 wt% of the medicated feed premix.
  • the medicated feed premix also comprises a carrier.
  • Suitable carriers include, for example, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, calcium carbonate, and combinations comprising one or more of the foregoing carriers.
  • the carrier comprises calcium sulfate.
  • the carrier comprises 20 wt% to 85 wt% of the total weight of the medicated feed premix, specifically 30 wt% to 75 wt% of the medicated feed premix.
  • the medicated feed premix optionally comprises a pH regulator.
  • the carrier e.g., calcium sulfate
  • Suitable pH regulators include acids and bases suitable to adjust the pH to the desired level.
  • the pH regulator comprises a base such as an alkali metal or alkaline earth metal hydroxide, including sodium hydroxide, potassium hydroxide, calcium hydroxide, and combinations comprising one or more of the foregoing pH regulators.
  • the pH regulator comprises 0 wt% to 5 wt% of the total weight of the medicated feed premix, specifically 0.1 wt% to 2 wt.% of the medicated feed premix.
  • the medical feed premix may comprise additional additives such as fillers, lubricants, disintegrants, and combinations thereof.
  • the pH of the medicated feed premix is between 3 and 4 in order to prevent significant degradation towards degradants with know toxicity profiles such as the anhydro or iso forms of tetracycline. It was unexpected that such a low pH can provide a chlortetracycline medicated feed premix having exceptional stability.
  • the pharmaceutically acceptable tetracycline, carrier, binder and optional pH regulator are combined to form the medicated feed premix.
  • the medicated feed premix is a multiparticulate composition.
  • the term multiparticulate is intended to refer broadly to small particles regardless of their composition or the manner in which they are formed.
  • the particles generally are of a mean diameter of about 40 to about 3000 ⁇ m, specifically about 30 to about 1000 ⁇ m.
  • the tetracycline, carrier and binder are granulated to form the medicated feed premix.
  • Advantages of a granular formulation include: higher stability due to the physical seclusion of the tetracycline from the environment; higher stability due to the chemical protection by the carrier; better mixability due to the match in particle size of the feed and the product; less risk for carry over or cross contamination to other feeds produced 7 004221
  • Granulation is a process by which relatively small particles are built up into larger granular particles.
  • Tn wet-granulation a liquid is used to increase the intermolecular forces between particles, leading to an enhancement in granular integrity, referred to as the "strength" of the granule.
  • liquids found to be effective wet-granulation liquids include water, ethanol, isopropyl alcohol and acetone.
  • the wet- granulation liquid is water at pH 7 or higher.
  • the components of the medicated feed premix are formed into a mixture and the mixture is granulated to form the granulate.
  • tetracycline- containing multiparticulates examples include fluidized bed granulation, rotary granulation and high-shear mixers.
  • fluidized bed granulation air is used to agitate or "fluidize" particles of chlortetracycline and/or carrier in a fluidizing chamber. The liquid is then sprayed into this fluidized bed, forming the granules.
  • rotary granulation horizontal discs rotate at high speed, forming a rotating "rope" of tetracycline and/or carrier particles at the walls of the granulation vessel. The liquid is sprayed into this rope, forming the granules.
  • High-shear mixers contain an agitator or impeller to mix the particles of chlortetracycline and/or carrier.
  • the liquid is sprayed into the moving bed of particles, forming granules.
  • the liquid preferably comprises the binder and optional pH regulator.
  • all or a portion of the carrier can be dissolved into the liquid prior to spraying the liquid onto the particles.
  • the particles are formed by extruding the liquid mixture into a solid mass followed by spheronizing or milling the mass.
  • the liquid mixture which is in the form of a paste-like plastic suspension, is extruded through a perforated plate or die to form a solid mass, often in the form of elongated, solid rods.
  • This solid mass is then milled to form the multiparticulates.
  • the solid mass is placed, with or without an intervening drying step, onto a rotating disk that has protrusions that break the material into multiparticulate spheres, spheroids, or rounded rods.
  • a portion of the liquid is removed, typically in a drying step, thus forming the multiparticulates.
  • at least 80% of the liquid is removed from the particles, more preferably at least 90%, and most preferably at least 95% of the liquid is removed from the particle during the drying step.
  • the multiparticulates may also be made by a granulation process comprising the steps of (a) forming a solid mixture comprising tetracycline, a carrier, a binder, and optionally a pH regulator; and (b) granulating the solid mixture to form multiparticulates.
  • a granulation process comprising the steps of (a) forming a solid mixture comprising tetracycline, a carrier, a binder, and optionally a pH regulator; and (b) granulating the solid mixture to form multiparticulates.
  • granulation processes include dry granulation and melt granulation, both well known in the art.
  • roller compaction An example of a dry granulation process is roller compaction.
  • the solid mixture is compressed between rollers.
  • the rollers can be designed such that the resulting compressed material is in the form of small beads or pellets of the desired diameter.
  • the compressed material is in the form of a ribbon that may be milled to for multiparticulates using methods well known in the art.
  • melt granulation processes the solid mixture is fed to a granulator that has 1 the capability of heating or melting the carrier.
  • Equipment suitable for use in this process includes high-shear granulators and single or multiple screw extruders, such as those described above for melt-congeal processes.
  • melt granulation processes the solid mixture is placed into the granulator and heated until the solid mixture agglomerates. The solid mixture is then kneaded or mixed until the desired particle size is attained. The so-formed granules are then cooled, removed from the granulator and sieved to the desired size fraction, thus forming the multiparticulates.
  • the medicated feed premixes are blended with an animal foodstuff to produce a medicated finished complete or supplement feed product.
  • Animals to which the medicated feed premixes may be administered include pets or companion animals, and ranch or farm animals or other livestock, such as animals raised as a food source or for another commercial purpose. Such animals include, but are not limited to, cattle, sheep, 2007/004221
  • a medicated animal feed composition is prepared by adding a medicated feed premix to an animal feedstuff.
  • the medicated feed premix may be added to the feedstuff in a number of ways.
  • the medicated feed premix containing a given quantity of chlortetracycline may be added to a given quantity of feed and mixed or blended to provide a substantially homogeneous medicated feed composition.
  • Large feed lots may be prepared in this manner for treating a large number of animals.
  • feed batches containing feed for a single animal or single meal may be prepared either by mixing a predetermined quantity of medicated feed premix with the animal feed or by adding a predetermined quantity of premix to an animal's feed as a top dressing.
  • Manufactured foodstuffs for animals such as cattle, pigs, and fowl are usually provided in the form of pellets or similar particulate material.
  • Pellets are typically manufactured by combining a cereal base with ingredients such as oil and protein, steam conditioning the mixture (for example at 70°C for 5 minutes), extruding through a circular die (typically between 2 mm and 15 mm in diameter), cutting into appropriately sized lengths (e.g., 5-20 mm), and drying.
  • the finished pellets are generally cylindrically shaped and have a relatively smooth surface.
  • the concentration of the active ingredient in the final medicated feed mixture may be adjusted to meet particular needs and maybe varied over a wide range.
  • An effective amount of the medicated feed premix is added to the feedstuff.
  • the minimum concentration should be such as to achieve the desired result (therapeutic, prophylactic, growth enhancement, etc.).
  • the maximum concentration should be such as to avoid any undesirable side effects when the feed rations are ingested by the animal.
  • specific amounts of active ingredient will normally be regulated by the practitioner according to potency of the medicated feed premix and the usual recommended dosing levels for the active ingredient. The practitioner will generally take into account a number of factors, such as the animal species being treated, the animal's age or stage of development, the frequency T/US2007/00422!
  • the medicated feed premix may in this case be mixed with feedstuffs or with drinking water.
  • the tetracycline concentrations in feedstuffs or in drinking water may vary within certain limits.
  • the chlortetracycline concentrations are in general between 5 and 2000 ppm, specifically between 10 and 1000 ppm, and more specifically between 10 and 500 ppm in the feedstuff or drinking water.
  • the treatment method can also be extended to other methods for treating and feeding animals.
  • the medicated feed premix may be combined with other active substances, such as, for example, with other anti-coccidial agents.
  • a method of combating microbial infection in animals such as pigs, wherein the medicated feed premixes are administered orally ad lib, and in particular, either as feedstuff or by means of drinking water.
  • Tetracyclines degrade, for example, by reversible epimerization to the less active 4-epitetracycline.
  • the degree of epimerization is dependent upon pH, and is greatest at a pH of approximately 3.
  • the rate of epimerization is also affected by temperature and the presence of phosphate or citrate ions.
  • Other degradation routes include anhydration and isomerization which typically become important outside of the pH 2.5 to 5 range.
  • Figure 1 illustrates various degradation routes of tetracycline.
  • Step no. 1 Weighing of the starting materials: The 25% chlortetracycline animal feed supplement is formulated by using chlortetracycline hydrochloride, calcium sulfate dihydrate and sodium carboxymethylcellulose.
  • Step no. 2 Mixing: The weighed starting materials are unloaded into a horizontal ribbon blender. The nominal load is 1 metric ton. The blender is positioned on load cells, and the actual weight is measured and recorded.
  • Chlortetracycline hydrochloride 25% (w/w) of batch size
  • the mixing time is 20 minutes at a mixing speed of 16 rpm.
  • Step no. 3 Granulation: After blending, the powder mix is transferred to a hopper. The hopper gradually feeds the "High Shear Granulation” (HSG) unit. The granulator processes a sequential relatively small amount of material (approximately 3 kg). The HSG-unit consists of two parts. The first part is the wetting phase. Water, of potable quality, is metered into the granulator by means of a dosing pump. The second part is the granulation phase, where wet granules are formed. The parameters for granulation are automatically controlled by PLC (Programmable Logic Controller).
  • PLC Programmable Logic Controller
  • Step no. 4 Drying: Afterwards, the wet granules are transferred to a fluidized bed dryer (hot air dryer). The temperature of the product in the fluid bed dryer is maintained between 35°C and 50 0 C. The parameters for drying are automatically controlled by PLC (Programmable Logic Controller).
  • PLC Programmable Logic Controller
  • Step no. 5 Sieving: After drying step, the dry granules are sieved through a vibrating screen, in order to achieve the specified particle size. Oversized granules (> 1180 ⁇ m) are milled, and are collected together with the fines ( ⁇ 300 ⁇ m) in a hopper. This hopper feeds the high shear granulator. The re-granulated product is dried and sieved again.
  • Step no. 6 Homogenization: The product (in range with the particle size) leaves the vibrating screen and is collected in a hopper until the end of the granulation production. Prior to packaging the granules are homogenized in a second mixer for 5 minutes.
  • Step no. 7 Packaging: The final step after sieving at the end of the manufacturing process is the packing of the finished product in polyethylene bags. From the second mixer, the granules are moved over the funnel to the packaging unit.
  • Table 1 shows the stability of different batches of medicated feed premixes stored in paper or plastic as the percentage of chlortetracycline remaining in the formulation.
  • Time points were 1 month (TlM), 3 months (T3M), 9 months (T9M), 12 months, (Tl 2M), eighteen months (T18M), and 24 months (T24M).
  • RH denotes the relative humidity in the storage conditions.
  • Table 2 Comparative example- Summary results on the recovery and stability of chlortetracycline hydrochloride in pig mash and pelleted feeds supplemented with 10% chlortetracycline feed premix
  • Table 3 Summary results on the recovery and stability of chlortetracycline hydrochloride in pig mash and pelleted feeds supplemented with 25% Chlortetracycline feed premix
  • Tables 2 and 3 summarize the stability of the 10% chlortetracycline feed premix compared to 25% in different types of feed: Mash and pellets.
  • the 10% and 25% chlortetracycline hydrochloride preniixes perform well in mash feed, but differ in pellets. Where the 10% fails completely at T2M (failing is a percentage below 75%), acceptable results at T3M for the 25% supplement are observed.
  • Disclosed herein are chlortetracycline animal feed compositions comprising pharmaceutically acceptable chlortetracycline hydrochloride.
  • the compositions have the advantage of compliance with EU regulations as given in Directive 2001/82EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products-Annex 1. C.
  • Other advantages include shelf stability, stability in feed, safety for both the animal and the consumer, and improved availability to the animal.
  • use of a granular formulation provides both user convenience and consumer safety.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Disclosed herein are tetracycline medicated feed premixes and methods for the stabilization thereof. In one embodiment, a medicated feed premix comprises 15 wt% to 65 wt% of a pharmaceutically acceptable chlortetracycline hydrochloride, 20 wt% to 85 wt% of a carrier, and 0.1 wt% to 10 wt% of a binder, wherein all amounts are based on the total weight of the animal feed supplement. Also included are methods of making a medicated feed premix, the use of a chlortetracycline hydrochloride in the manufacture of a medicament for treating microbial infections in animals, and an animal feed composition.

Description

MEDICATED FEED PREMIX COMPRISING CHLORTETRACYCLINE HYDROCHLORIDE
BACKGROUND
[0001] Antibiotics, such as tetracyclines, are used as growth promoters and feed efficiency promoters in animals such as poultry and livestock, and for therapeutic and prophylactic disease control in animals such as poultry and livestock, fish, domesticated pets, and so forth. Such antibiotics are typically formulated in a medicated animal feed premix or animal feed supplement containing the antibiotic and an edible carrier or diluent. These premixes or animal feed supplements may then be mixed with a sufficient quantity of an appropriate animal foodstuff (e.g., livestock, poultry, fish, pet and/or other animal feed) to provide a final animal feed formulation having the desired level of antibiotic in the feed.
[0002] Typical prior art chlortetracycline-containing animal feed premixes are prepared through normal fermentation and dehydration of the mycelium meal, which is added directly to the feed premix. Streptomyces aureofaciens is a microbial source organism for chlortetracycline. Under a normal fermentation and dehydration processes, feed premixes comprising about 20 wt% or less of chlortetracycline have been produced. U.S. Patent Number 6,844,006 describes animal feed premixes containing greater than 35 wt% chlortetracycline produced using a novel fermentation process in which the chlortetracycline is also added directly from a fermentation product.
[0003] Another problem with prior tetracycline (e.g, chlortetracycline) animal feed premixes is the stability of the tetracycline in these premixes. Because tetracyclines are water soluble, there is intrinsically an issue with stability in finished feeds containing moistures of 10% or higher. The higher water activity (relative vapor pressure) of feedstuff compared to tetracycline leads to an inevitable increase of the humidity of most formulations.
[0004] There thus remains a need for alternative animal feed premixes comprising tetracyclines. BRIEF SUMMARY
[0005] The above-described and other drawbacks are alleviated by an a medicated feed premix composition comprising 15 wt% to 65 wt% of a pharmaceutically acceptable chlortetracycline hydrochloride, 20 wt% to 85 wt% of a carrier, and 0.1 wt% to 10 wt% of a binder, wherein all amounts are based on the total weight of the medicated feed premix. Also included is an animal feed composition comprising an. effective amount of the medicated feed premix.
[0006] In one embodiment, included is the use of a chlortetracycline hydrochloride in the manufacture of a medicament for treating microbial infections in animals. The medicament comprises 15 wt% to 65 wt% of a pharmaceutically acceptable chlortetracycline hydrochloride, 20 wt% to 85 wt% of a carrier, and 0.1 wt% to 10 wt% of abinder, wherein all amounts are based on the total weight of the medicament. ,
[0007] In another embodiment, a method of making an a medicated feed premix comprises forming a mixture comprising 15 wt% to 65 wt% of a pharmaceutically acceptable chlortetracycline hydrochloride, 20 wt% to 85 wt% of a carrier,' 0.1 wt% to 10 wt% of a binder, wherein all amounts are based on the total weight of the medicated feed premix; and granulating the mixture to form a granulate.
[0008] In yet another embodiment, a medicated feed premix comprises 15 wt% to 65 wt% of a pharmaceutically acceptable tetracycline hydrochloride, 20 wt% to 85 wt% of a carrier, and 0.1 wt% to 10 wt% of a binder, wherein all amounts are based on the total weight of the animal feed supplement, and wherein the medicated feed premix is in the form of a granulate and has a pH of 3 to 4.
[0009] The above-described and other features will be appreciated and understood by those skilled in the art from the following detailed description and appended claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 illustrates degradation routes of chlortetracycline. DETAILED DESCRIPTION
[0011] Disclosed herein are medicated feed premixes comprising pharmaceutically acceptable tetracycline (e.g., chlortetracycline hydrochloride), a binder, and a carrier. A "medicated feed premix" refers to a composition suitable for incorporation into the diet of an animal through incorporation into the animal's food and/or water. In one embodiment, the medicated feed premix is in the form of a granulate. Medicated feed premixes are also referred to as feed "supplement" compositions and "feed additive" compositions.
[0012] As used herein, the term tetracycline includes tetracycline, chlortetracycline, oxytetracycline, doxycycline, demeclocycline, lymecycline, meclocycline, methacycline, minocycline, rolitetracycline, and combinations comprising one or more of the foregoing tetracyclines. Included in the term tetracycline are salts, esters, ethers, isomers, mixtures of isomers, complexes or derivatives of the free compoundand combinations comprising one or more of the foregoing tetracyclines! In one embodiment, the tetracycline is chlortetracycline hydrochloride.
[0013] Since chlortetracycline hydrochloride is the reference standard for chlortetracycline feed grade materials, all chlortetracycline concentrations and percentages stated herein, unless indicated otherwise, are calculated as the hydrochloride equivalent, regardless of the form present (e.g., the free base, complexes or salts other than the hydrochloride, etc.)
[0014] Directive 2001/82EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products— Annex 1. C, describes control of starting materials. In particular, section 1.1 applies to starting materials listed in pharmacopoeias, stating in part "The monographs of the European Pharmacopoeia (EP) shall be applicable to all substances appearing in it." The term "pharmaceutically acceptable" as used herein means a tetracycline ( e.g., chlortetracycline hydrochloride) as listed in the European Pharmacopia, such as the 5th edition of the European Pharmacopia. In one embodiment, pharmaceutically acceptable chlortetracycline hydrochloride comprises a minimum of 89.5 wt% anhydrous chlortetracycline hydrochloride and a maximum of 8 wt% anhydrous tetracycline, with a 94.5-102 wt% sum of anhydrous chlortetracycline hydrochloride plus anhydrous tetracycline hydrochloride. • [0015] The medicated feed premixes described herein can be distinguished from prior art tetracycline medicated feed premixes in that the medicated feed premixes described herein comprise pharmaceutically acceptable tetracycline. Pharmaceutically acceptable chlortetracycline hydrochloride, for example, is typically prepared by chemical purification of chlortetracycline hydrochloride produced by fermentation, typically of Streptomyces aureofaciens. Prior art chlortetracycline medicated feed premixes contain chlortetracycline hydrochloride in the form of a crude fermentation product such as that produced by dehydration of the mycelium meal. Thus, pharmaceutically acceptable chlortetracycline is produced by chemical purification. In one embodiment, the chlortetracycline hydrochloride is not produced from genetically modified organisms.
[0016] The pharmaceutically acceptable tetracycline (e.g., chlortetracycline hydrochloride) comprises 15 wt% to 65 wt% of the total weight of the medicated feed premix, specifically 20 wt% to 65 wt% of the total weight of the medicated feed premix, more specifically 25 wt% to 65 wt% of the medicated feed premix, and most specifically 25 wt% to 60 wt% of the medicated feed premix.
[0017] The medicated feed premix also comprises a binder. The term "binder" is well known to those of skill in the art as an agent that holds the components of the formulation together. Suitable binders include, for example, sodium carboxymethylcellulose, hydroxyprppylmethylcellulose, gelatin, polyvinylpyrrolidone (PVP), polyvinylalcohol, polyvinylether, hydroxypropylcellulose, potassium alginate, sodium alginate, ethyl cellulose, methylcellulose, macrocrystalline cellulose, starch such as partially pregelatinized corn starch, and combinations comprising one or more of the foregoing binders. In one embodiment, the binder comprises sodium carboxymethylcellulose.
[0018] The binder comprises 0.1 wt%. to 10 wt% of the total weight of the medicated feed premix, specifically 0.2 wt% to 5 wt% of the medicated feed premix.
[0019] The medicated feed premix also comprises a carrier. Suitable carriers include, for example, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, calcium carbonate, and combinations comprising one or more of the foregoing carriers. In one embodiment, the carrier comprises calcium sulfate. US2007/004221
[0020] The carrier comprises 20 wt% to 85 wt% of the total weight of the medicated feed premix, specifically 30 wt% to 75 wt% of the medicated feed premix.
[0021] The medicated feed premix optionally comprises a pH regulator. In some embodiments, the carrier (e.g., calcium sulfate) is sufficient to maintain the pH of the composition, although it is possible to add an additional pH regulator. Suitable pH regulators include acids and bases suitable to adjust the pH to the desired level. In one embodiment, the pH regulator comprises a base such as an alkali metal or alkaline earth metal hydroxide, including sodium hydroxide, potassium hydroxide, calcium hydroxide, and combinations comprising one or more of the foregoing pH regulators.
[0022] The pH regulator comprises 0 wt% to 5 wt% of the total weight of the medicated feed premix, specifically 0.1 wt% to 2 wt.% of the medicated feed premix.
[0023] The medical feed premix may comprise additional additives such as fillers, lubricants, disintegrants, and combinations thereof.
[0024] In one embodiment, the pH of the medicated feed premix is between 3 and 4 in order to prevent significant degradation towards degradants with know toxicity profiles such as the anhydro or iso forms of tetracycline. It was unexpected that such a low pH can provide a chlortetracycline medicated feed premix having exceptional stability.
[0025] The pharmaceutically acceptable tetracycline, carrier, binder and optional pH regulator are combined to form the medicated feed premix. In one embodiment, the medicated feed premix is a multiparticulate composition. The term multiparticulate is intended to refer broadly to small particles regardless of their composition or the manner in which they are formed. The particles generally are of a mean diameter of about 40 to about 3000 μm, specifically about 30 to about 1000 μm.
[0026], In one embodiment, the tetracycline, carrier and binder are granulated to form the medicated feed premix. Advantages of a granular formulation include: higher stability due to the physical seclusion of the tetracycline from the environment; higher stability due to the chemical protection by the carrier; better mixability due to the match in particle size of the feed and the product; less risk for carry over or cross contamination to other feeds produced 7 004221
6
in the same plant; less health risks for the operators handling the product; and better mechanical properties such as flowability.
[0027] Granulation is a process by which relatively small particles are built up into larger granular particles. Tn wet-granulation, a liquid is used to increase the intermolecular forces between particles, leading to an enhancement in granular integrity, referred to as the "strength" of the granule. Examples of liquids found to be effective wet-granulation liquids include water, ethanol, isopropyl alcohol and acetone. In one embodiment, the wet- granulation liquid is water at pH 7 or higher.
[0028] In an exemplary granulation process, the components of the medicated feed premix are formed into a mixture and the mixture is granulated to form the granulate.
[0029] Several types of wet-granulation processes can be used to form tetracycline- containing multiparticulates. Examples include fluidized bed granulation, rotary granulation and high-shear mixers. In fluidized bed granulation, air is used to agitate or "fluidize" particles of chlortetracycline and/or carrier in a fluidizing chamber. The liquid is then sprayed into this fluidized bed, forming the granules. In rotary granulation, horizontal discs rotate at high speed, forming a rotating "rope" of tetracycline and/or carrier particles at the walls of the granulation vessel. The liquid is sprayed into this rope, forming the granules. High-shear mixers contain an agitator or impeller to mix the particles of chlortetracycline and/or carrier. The liquid is sprayed into the moving bed of particles, forming granules. In these processes, the liquid preferably comprises the binder and optional pH regulator. Also in these processes, all or a portion of the carrier can be dissolved into the liquid prior to spraying the liquid onto the particles. Thus, in these processes, the steps of forming the liquid mixture and forming particles from the liquid mixture occur simultaneously. i
[0030] In another embodiment, the particles are formed by extruding the liquid mixture into a solid mass followed by spheronizing or milling the mass. In this process, the liquid mixture, which is in the form of a paste-like plastic suspension, is extruded through a perforated plate or die to form a solid mass, often in the form of elongated, solid rods. This solid mass is then milled to form the multiparticulates. In one embodiment, the solid mass is placed, with or without an intervening drying step, onto a rotating disk that has protrusions that break the material into multiparticulate spheres, spheroids, or rounded rods. The so- 007/004221
formed multiparticulates are then dried to remove any remaining liquid. This process is sometimes referred to in the pharmaceutical arts as an extrusion/spheronization process.
[0031] Once the particles are formed, a portion of the liquid is removed, typically in a drying step, thus forming the multiparticulates. Preferably, at least 80% of the liquid is removed from the particles, more preferably at least 90%, and most preferably at least 95% of the liquid is removed from the particle during the drying step.
[0032] The multiparticulates may also be made by a granulation process comprising the steps of (a) forming a solid mixture comprising tetracycline, a carrier, a binder, and optionally a pH regulator; and (b) granulating the solid mixture to form multiparticulates. Examples of such granulation processes include dry granulation and melt granulation, both well known in the art.
[0033] An example of a dry granulation process is roller compaction. In roller compaction processes, the solid mixture is compressed between rollers. The rollers can be designed such that the resulting compressed material is in the form of small beads or pellets of the desired diameter. Alternatively, the compressed material is in the form of a ribbon that may be milled to for multiparticulates using methods well known in the art.
[0034] In a melt granulation processes, the solid mixture is fed to a granulator that has1 the capability of heating or melting the carrier. Equipment suitable for use in this process includes high-shear granulators and single or multiple screw extruders, such as those described above for melt-congeal processes. In melt granulation processes, the solid mixture is placed into the granulator and heated until the solid mixture agglomerates. The solid mixture is then kneaded or mixed until the desired particle size is attained. The so-formed granules are then cooled, removed from the granulator and sieved to the desired size fraction, thus forming the multiparticulates.
[0035] In one embodiment, the medicated feed premixes are blended with an animal foodstuff to produce a medicated finished complete or supplement feed product. Animals to which the medicated feed premixes may be administered include pets or companion animals, and ranch or farm animals or other livestock, such as animals raised as a food source or for another commercial purpose. Such animals include, but are not limited to, cattle, sheep, 2007/004221
S
horses, pigs, buffalo, goats, dogs, cats, rabbits, rats, mice, minks, fish, and fowl (including egg-laying or edible fowl, such as chickens, turkeys, geese, ducks, quail, pheasant, etc.), and the like.
[0036] In one embodiment, a medicated animal feed composition is prepared by adding a medicated feed premix to an animal feedstuff. The medicated feed premix may be added to the feedstuff in a number of ways. The medicated feed premix containing a given quantity of chlortetracycline may be added to a given quantity of feed and mixed or blended to provide a substantially homogeneous medicated feed composition. Large feed lots may be prepared in this manner for treating a large number of animals. Alternatively, feed batches containing feed for a single animal or single meal may be prepared either by mixing a predetermined quantity of medicated feed premix with the animal feed or by adding a predetermined quantity of premix to an animal's feed as a top dressing.
[0037] Manufactured foodstuffs for animals such as cattle, pigs, and fowl are usually provided in the form of pellets or similar particulate material. Pellets are typically manufactured by combining a cereal base with ingredients such as oil and protein, steam conditioning the mixture (for example at 70°C for 5 minutes), extruding through a circular die (typically between 2 mm and 15 mm in diameter), cutting into appropriately sized lengths (e.g., 5-20 mm), and drying. The finished pellets are generally cylindrically shaped and have a relatively smooth surface.
[0038] By varying the quantity of medicated feed premix added to the animal feedstuff, the concentration of the active ingredient in the final medicated feed mixture may be adjusted to meet particular needs and maybe varied over a wide range. An effective amount of the medicated feed premix is added to the feedstuff. The minimum concentration should be such as to achieve the desired result (therapeutic, prophylactic, growth enhancement, etc.). The maximum concentration should be such as to avoid any undesirable side effects when the feed rations are ingested by the animal. Within these limitations, specific amounts of active ingredient will normally be regulated by the practitioner according to potency of the medicated feed premix and the usual recommended dosing levels for the active ingredient. The practitioner will generally take into account a number of factors, such as the animal species being treated, the animal's age or stage of development, the frequency T/US2007/00422!
of administration, whether the composition is being administered therapeutically or prophylactically and the degree of antimicrobial results sought, the severity of any disease being treated, and so forth. The selection of dosages and dosage regimens is generally performed as a routine matter by persons skilled in the arts pertaining to veterinary medicine, animal husbandry and nutrition, and the like. Accordingly, the indications and dosage levels given herein are intended to be exemplary and illustrative only, and are not intended to be exhaustive or restrictive of the present invention as claimed.
[0039] The medicated feed premix may in this case be mixed with feedstuffs or with drinking water. The tetracycline concentrations in feedstuffs or in drinking water may vary within certain limits. The chlortetracycline concentrations are in general between 5 and 2000 ppm, specifically between 10 and 1000 ppm, and more specifically between 10 and 500 ppm in the feedstuff or drinking water.
[0040] The treatment method can also be extended to other methods for treating and feeding animals. Thus, for example, the medicated feed premix may be combined with other active substances, such as, for example, with other anti-coccidial agents.
[0041] In one embodiment, a method of combating microbial infection in animals such as pigs, wherein the medicated feed premixes are administered orally ad lib, and in particular, either as feedstuff or by means of drinking water.
[0042] In another embodiment, included are methods of improving the stability of tetracycline medicated feed premixes. Tetracyclines degrade, for example, by reversible epimerization to the less active 4-epitetracycline. The degree of epimerization is dependent upon pH, and is greatest at a pH of approximately 3. The rate of epimerization is also affected by temperature and the presence of phosphate or citrate ions. Other degradation routes include anhydration and isomerization which typically become important outside of the pH 2.5 to 5 range. Figure 1 illustrates various degradation routes of tetracycline.
[0043] Unexpectedly, it has been discovered that the stability of the tetracycline medicated feed premix is improved by adjusting the pH of the premix to 3 to 4. At pH 3 to 4, the premix is in a range where tetracycline degradation is a high risk, but with a predominant route which evades degradation to potentially toxic components. US2007/004221
10
[0044] The invention is further illustrated by the following non-limiting examples.
EXAMPLES
Preparation of 25% chlortetracycline medicated feed premix
[0045] Step no. 1 : Weighing of the starting materials: The 25% chlortetracycline animal feed supplement is formulated by using chlortetracycline hydrochloride, calcium sulfate dihydrate and sodium carboxymethylcellulose.
[0046] Step no. 2: Mixing: The weighed starting materials are unloaded into a horizontal ribbon blender. The nominal load is 1 metric ton. The blender is positioned on load cells, and the actual weight is measured and recorded.
[0047] The sequence of adding the starting materials to the mixer is as follows:
Calcium sulfate dihydrate: 40% of batch size
Chlortetracycline hydrochloride: 25% (w/w) of batch size
Sodium carboxymethylcellulose: 3% of batch size
Calcium sulfate dihydrate: up to 100% of batch size
[0048] The mixing time is 20 minutes at a mixing speed of 16 rpm.
[0049] Step no. 3: Granulation: After blending, the powder mix is transferred to a hopper. The hopper gradually feeds the "High Shear Granulation" (HSG) unit. The granulator processes a sequential relatively small amount of material (approximately 3 kg). The HSG-unit consists of two parts. The first part is the wetting phase. Water, of potable quality, is metered into the granulator by means of a dosing pump. The second part is the granulation phase, where wet granules are formed. The parameters for granulation are automatically controlled by PLC (Programmable Logic Controller).
[0050] Step no. 4: Drying: Afterwards, the wet granules are transferred to a fluidized bed dryer (hot air dryer). The temperature of the product in the fluid bed dryer is maintained between 35°C and 500C. The parameters for drying are automatically controlled by PLC (Programmable Logic Controller).
[0051] Step no. 5: Sieving: After drying step, the dry granules are sieved through a vibrating screen, in order to achieve the specified particle size. Oversized granules (> 1180 μm) are milled, and are collected together with the fines (< 300 μm) in a hopper. This hopper feeds the high shear granulator. The re-granulated product is dried and sieved again.
[0052] Step no. 6: Homogenization: The product (in range with the particle size) leaves the vibrating screen and is collected in a hopper until the end of the granulation production. Prior to packaging the granules are homogenized in a second mixer for 5 minutes.
[0053] Step no. 7: Packaging: The final step after sieving at the end of the manufacturing process is the packing of the finished product in polyethylene bags. From the second mixer, the granules are moved over the funnel to the packaging unit.
Results
[0054] Three batches of 25% chlortetracycline medicated feed premixes were compared for shelf stability stored in paper and plastic. Table 1 shows the stability of different batches of medicated feed premixes stored in paper or plastic as the percentage of chlortetracycline remaining in the formulation. Time points were 1 month (TlM), 3 months (T3M), 9 months (T9M), 12 months, (Tl 2M), eighteen months (T18M), and 24 months (T24M). RH denotes the relative humidity in the storage conditions.
Table 1 : Overview Stability 25% Chlortetracycline feed premixes
-: No analysis required according to protocol.
[0055] Both 10% and 25% chlortetracycline hydrochloride feed premixes were produced and then mixed into either a commercial mash feed or a commercial pellet feed composition at 500 ppm with a planetary mixer. The amount of chlortetracycline was measured by HPLC analysis.
Table 2: Comparative example- Summary results on the recovery and stability of chlortetracycline hydrochloride in pig mash and pelleted feeds supplemented with 10% chlortetracycline feed premix
Table 3: Summary results on the recovery and stability of chlortetracycline hydrochloride in pig mash and pelleted feeds supplemented with 25% Chlortetracycline feed premix
[0056] Tables 2 and 3 summarize the stability of the 10% chlortetracycline feed premix compared to 25% in different types of feed: Mash and pellets. The 10% and 25% chlortetracycline hydrochloride preniixes perform well in mash feed, but differ in pellets. Where the 10% fails completely at T2M (failing is a percentage below 75%), acceptable results at T3M for the 25% supplement are observed. [0057] Disclosed herein are chlortetracycline animal feed compositions comprising pharmaceutically acceptable chlortetracycline hydrochloride. The compositions have the advantage of compliance with EU regulations as given in Directive 2001/82EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products-Annex 1. C. Other advantages include shelf stability, stability in feed, safety for both the animal and the consumer, and improved availability to the animal. In addition, use of a granular formulation provides both user convenience and consumer safety.
[0058] The use of the terms "a" and "an" and "the" and similar referents (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms first, second etc. as used herein are not meant to denote any particular ordering, but simply for convenience to denote a plurality. The terms "comprising", "having", "including", and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to") unless otherwise'noted. Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The endpoints of all ranges are included within the range and independently combinable. All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as"), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention as used herein.
[0059] While the invention has been described with reference to an exemplary embodiment, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments falling within the scope of the appended claims. Any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
[0060] All cited patents, patent applications, and other references are incorporated herein by reference in their entirety.

Claims

CLAIMS:
1. A medicated feed premix, comprising:
15 wt% to 65 wt% of a pharmaceutically acceptable chlortetracycline hydrochloride,
20 wt% to 85 wt% of a carrier, and
0.1 wt% to 10 wt% of a binder,
wherein all amounts are based on the total weight of the medicated feed premix.
2. The medicated feed premix of claim 1, wherein the binder comprises sodium carboxymethylcellulose.
3. • The medicated feed premix of claim 1, wherein the carrier comprises calcium sulfate.
4. The medicated feed premix of claim 1, having a pH of 3 to 4.
5. The medicated feed premix of claim 1, comprising 20 wt% to 65 wt% of the pharmaceutically acceptable chlortetracycline hydrochloride.
6. The medicated feed premix of claim 1, wherein the pharmaceutically acceptable chlortetracycline hydrochloride comprises a minimum of 89.5 wt% anhydrous chlortetracycline hydrochloride and a maximum of 8 wt% anhydrous tetracycline, with a 94.5-102 wt% sum of anhydrous chlortetracycline hydrochloride plus anhydrous tetracycline hydrochloride.
7. The medicated feed premix of claim I5 in the form of a multiparticulate composition. .
8. The medicated feed premix of claim 7, wherein the multiparticulate composition is a granulate.
9. The use of a chlortetracycline hydrochloride in the manufacture of a medicament for treating microbial infections in animals, wherein the medicament comprises:
20 wt% to 65 wt% of a pharmaceutically acceptable chlortetracycline hydrochloride,
20 wt% to 85 wt% of a carrier, and
0.1 wt% to 10 wt% of a binder,
wherein all amounts are based on the total weight of the medicament.
10. The use of claim 9, wherein the medicament is administered either as a feedstuff or by means of drinking water.
11. The use of claim 9, wherein the carrier comprises calcium sulfate.
12. The use of claim 9, wherein the medicated feed premix has a pH of 3 to
4.
13. An animal feed composition comprising:
an animal foodstuff, and
an effective amount of a medicated feed premix comprising:
15 wt% to 65 wt% of a pharmaceutically acceptable chlortetracycline hydrochloride,
20 wt% to 85 wt% of a carrier, and
0.1 wt% to 10 wt% of a binder,
wherein all amounts are based on the total weight of the medicated feed premix.
14. The animal feed composition of claim 13, wherein the carrier comprises calcium sulfate.
15. The animal feed composition of claim 13, wherein the medicated feed premix has a pH of 3 to 4.
16. A medicated feed premix, comprising:
15 wt% to 65 wt% of a pharmaceutically acceptable tetracycline,
20 wt% to 85 wt% of a carrier, and
0.1 wt% to 10 wt% of a binder,
wherein all amounts are based on the total weight of the animal feed supplement, and
wherein the medicated feed premix is in the form of a granulate and has a pH of 3 to 4.
17. The medicated feed premix of claim 16, wherein the carrier comprises calcium sulfate.
18. The medicated feed premix of claim 16, wherein the medicated feed premix has a pH of 3 to 4.
19. The medicated feed premix of claim 16, comprising 20 wt% to 65 wt% of the pharmaceutically acceptable tetracycline.
TETRACYCLINE COMPOSITIONS AND METHODS
ABSTRACT
Disclosed herein are tetracycline medicated feed premixes and methods for the stabilization thereof. In one embodiment, a medicated feed premix comprises 15 wt% to 65 wt% of a pharmaceutically acceptable chlortetracycline hydrochloride, 20 wt% to 85 wt% of a carrier, and 0.1 wt% to 10 wt% of a binder, wherein all amounts are based on the total weight of the animal feed supplement. Also included are methods of making a medicated feed premix, the use of a chlortetracycline hydrochloride in the manufacture of a medicament for treating microbial infections in animals, and an animal feed composition.
EP07751014A 2007-02-16 2007-02-16 Medicated feed premix comprising chlortetracycline hydrochloride Active EP2007367B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI200730506T SI2007367T1 (en) 2007-02-16 2007-02-16 Medicated feed premix comprising chlortetracycline hydrochloride
CY20111100108T CY1111176T1 (en) 2007-02-16 2011-02-02 HYDROCHLORINE CHLOROTETRACYCLINE DRUG PREPARATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/004221 WO2008100262A1 (en) 2007-02-16 2007-02-16 Medicated feed premix comprising chlortetracycline hydrochloride

Publications (2)

Publication Number Publication Date
EP2007367A1 true EP2007367A1 (en) 2008-12-31
EP2007367B1 EP2007367B1 (en) 2010-12-22

Family

ID=38226372

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07751014A Active EP2007367B1 (en) 2007-02-16 2007-02-16 Medicated feed premix comprising chlortetracycline hydrochloride

Country Status (9)

Country Link
EP (1) EP2007367B1 (en)
AT (1) ATE492273T1 (en)
CY (1) CY1111176T1 (en)
DE (1) DE602007011418D1 (en)
DK (1) DK2007367T3 (en)
ES (1) ES2356395T3 (en)
PT (1) PT2007367E (en)
SI (1) SI2007367T1 (en)
WO (1) WO2008100262A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114099441A (en) * 2021-12-22 2022-03-01 金河牧星（重庆）生物科技有限公司 Chlortetracycline hydrochloride dry suspension and preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2962378A (en) * 1959-02-12 1960-11-29 American Cyanamid Co Animal feed composition
US3157512A (en) * 1960-06-22 1964-11-17 American Cyanamid Co Stabilization of animal and poultry feeds containing antibiotics
US3121634A (en) * 1961-04-03 1964-02-18 Monsanto Chemicals Animal feed compositions
BE653504A (en) * 1963-10-02 1965-03-24
US4081527A (en) * 1976-12-07 1978-03-28 Pfizer Inc. Chlortetracycline compositions
US6773717B1 (en) * 1999-07-09 2004-08-10 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
DE10114245A1 (en) * 2001-03-22 2002-10-02 Heraeus Kulzer Gmbh & Co Kg Production and use of an antibiotic / antibiotic preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008100262A1 *

Also Published As

Publication number Publication date
ATE492273T1 (en) 2011-01-15
PT2007367E (en) 2011-02-25
ES2356395T3 (en) 2011-04-07
EP2007367B1 (en) 2010-12-22
WO2008100262A1 (en) 2008-08-21
DE602007011418D1 (en) 2011-02-03
SI2007367T1 (en) 2011-04-29
CY1111176T1 (en) 2015-06-11
DK2007367T3 (en) 2011-04-11

Similar Documents

Publication Publication Date Title
JP2018109009A (en) Process for manufacturing chewable dosage forms for drug delivery and products thereof
CN103830187B (en) A kind of tilmicosin solid dispersal granule and its preparation method and application
JP2009518417A5 (en)
JP7402403B2 (en) Feed compositions containing hexahydro-β acid compounds, their uses, and methods for improving animal production performance
AU2002356740B2 (en) Micropherules containing a pleuromutilin derivative
CN107573253B (en) N, N-dimethyl glycine organic acid conjugate acid salt, composition and application thereof
WO2008123898A1 (en) Maduramicin compositions and methods
EP2007367B1 (en) Medicated feed premix comprising chlortetracycline hydrochloride
AU2009277180B2 (en) Laidlomycin compositions and methods
CN120168467A (en) An anthelmintic drug preparation and its preparation method and application
WO2009149012A1 (en) Laidlomycin compositions and methods
AU2009256444B2 (en) Lasalocid compositions and methods
CN111903701A (en) A kind of veterinary fly-killing premix and its preparation method and application
KR100337978B1 (en) Stabilized composition comprising colistin sulfate
WO2017013167A1 (en) A novel zilpaterol animal premix formulation
KR101109036B1 (en) Fenbendazole oral tablet complex composition
NL2020001B1 (en) Coated choline chloride granules
JPH0550257B2 (en)
HK1113974A (en) Compositions and methods for promoting weight gain and feed conversion

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081020

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20091008

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALPHARMA, LLC

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

BECA Be: change of holder's address

Owner name: ALPHARMA LLC400 CROSSING BOULEVARD, BRIDGEWATER, N

Effective date: 20101222

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602007011418

Country of ref document: DE

Date of ref document: 20110203

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007011418

Country of ref document: DE

Effective date: 20110203

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20110216

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: ALPHARMA, LLC

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2356395

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20110407

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20101222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20101222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110322

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 9049

Country of ref document: SK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110422

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E010624

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20111102

26N No opposition filed

Effective date: 20110923

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007011418

Country of ref document: DE

Effective date: 20110901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110901

REG Reference to a national code

Ref country code: HU

Ref legal event code: HC9C

Owner name: ZOETIS PRODUCTS LLC, US

Free format text: FORMER OWNER(S): ALPHARMA, LLC, US

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: ZOETIS PRODUCTS LLC

Effective date: 20130701

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: ZOETIS PRODUCTS LLC; US

Effective date: 20130725

REG Reference to a national code

Ref country code: SK

Ref legal event code: TC4A

Ref document number: E 9049

Country of ref document: SK

Owner name: ZOETIS PRODUCTS LLC, FLORHAM PARK, NEW JERSEY, US

Effective date: 20130723

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20150611 AND 20150617

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: ZOETIS SERVICES LLC, US

Effective date: 20150813

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: ZOETIS SERVICES LLC

Effective date: 20151019

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: ZOETIS SERVICES LLC; US

Effective date: 20151005

REG Reference to a national code

Ref country code: SK

Ref legal event code: PC4A

Ref document number: E 9049

Country of ref document: SK

Owner name: ZOETIS SERVICES LLC, FLORHAM PARK, NJ, US

Free format text: FORMER OWNER: ZOETIS PRODUCTS LLC, FLORHAM PARK, NEW JERSEY, US

Effective date: 20150911

REG Reference to a national code

Ref country code: HU

Ref legal event code: GB9C

Owner name: ZOETIS SERVICES LLC, US

Free format text: FORMER OWNER(S): ALPHARMA, LLC, US; ZOETIS PRODUCTS LLC, US

Ref country code: HU

Ref legal event code: FH1C

Free format text: FORMER REPRESENTATIVE(S): FRANKNE DR. MACHYTKA DAISY, GOEDOELLE, KEKES, MESZAROS & SZABO SZABADALMI ES VEDJEGY IRODA, HU

Representative=s name: DR. KOCSOMBA NELLI UEGYVEDI IRODA, HU

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20160210

Year of fee payment: 10

Ref country code: IE

Payment date: 20160126

Year of fee payment: 10

Ref country code: SK

Payment date: 20160201

Year of fee payment: 10

Ref country code: CZ

Payment date: 20160212

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20160218

Year of fee payment: 10

Ref country code: SI

Payment date: 20160209

Year of fee payment: 10

Ref country code: HU

Payment date: 20160202

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170228

REG Reference to a national code

Ref country code: HU

Ref legal event code: HC9C

Owner name: ZOETIS SERVICES LLC, US

Free format text: FORMER OWNER(S): ALPHARMA, LLC, US; ZOETIS PRODUCTS LLC, US

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170216

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170216

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 9049

Country of ref document: SK

Effective date: 20170216

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170217

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170217

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20171208

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170228

Ref country code: BE

Ref legal event code: PD

Owner name: ZOETIS SERVICES LLC; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), AFFECTATION / CESSION; FORMER OWNER NAME: ZOETIS PRODUCTS LLC

Effective date: 20150706

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170216

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170216

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20210211

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220216

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20250206

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20250110

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20260128

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20260310

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20260216

Year of fee payment: 20